Changes planned for Pharmaceutical Water in the Chinese Pharmacopoeia
Recommendation
28/29 January 2025
Generation, Monitoring & Compliance
The Chinese Pharmacopoeia Committee (CPC) intends to revise monograph 0261 Pharmaceutical Water, as well as the conductivity measurement (0681). In order to ensure the scientific validity and applicability of the changes, the proposed revised text is now being published to solicit professional feedback. The comment period will run until 24 July 2024, and although these are still proposals, it can be assumed that they will be adopted in their current form, presumably by the end of the year.
The planned changes include
- The authorisation of alternative methods for the production of WFI - that's the big news. However, purified water must still be used as feed water for the production of WFI. This is also the current requirement
- Abolition of chemical tests, as these are covered by the conductivity measurement
- Updating the conductivity method, which now corresponds to the USP method. The limit values for WFI correspond to both the USP and the European Pharmacopoeia. The limits for Purified Water are analogue to the higher EP limits compared to the USP
- A conductivity method for sterilised WFI has also been added, with limits analogous to USP & EP
- Greater emphasis on online testing methods
The planned changes are to be welcomed, as they represent further harmonisation between the various global pharmacopoeias.
Related GMP News
22.01.2025GMP Violations at Turkish OTC Manufacturer
15.01.2025Pharmaceutical Manufacturer obstructs FDA Inspection
11.12.2024Warning Letter to Indian Manufacturer of Sterile Ophthalmic Drop Products
06.11.2024FDA Warning Letter to a US Manufacturer of Medical Gases
30.10.2024WHO Guidance on Wastewater and Solid Waste Treatment in the Antibiotics Production
23.10.2024Warning Letter to Indian sterile Manufacturer due to Cross-Contamination and Particles